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Metabolism of contraceptive compounds may be influenced by various drugs. Of clinical importance is induction by barbiturates, by
diphenylhydantoin, and especially by rifampicin, of enzymes that are responsible for degradation of estrogens. The major target is the hepatic
microsomal estrogen-2-hydroxylase (cytochrome P450 3A4). Another type of interaction of drugs with disposition and effectiveness of estrogens is
impairment of their enterohepatic circulation. This may be due to absorption of biliary estrogen conjugates (e.g., by cholestyramine) or to insufficient
cleavage of the conjugate by intestinal bacteria, the latter being observed after administration of antibiotics (e.g., ampicillin, neomycin). -Environ
Health Perspect 102(Suppl 9):35-38 (1994)
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Introduction
The effectiveness of oral contraception
depends on unimpaired activity and action
of synthetic estrogens and gestagens. As
metabolism of contraceptive steroids is the
subject ofreviews (1-3), only those aspects
which are pertinent to drug interaction will
be mentioned here.
Major pathways of metabolism ofsyn-
thetic gestagens are reductive and include
ring A of the steroid (4). Hydroxylated
metabolites usually occur to a lesser extent.
By contrast, some animal experiments (5)
show that after barbiturate induction a
major metabolite of a synthetic gestagen
(chlormadinone acetate) is the 2-hydroxyla-
tion product (2-a-hydroxychlormadinone
acetate). This may be indicative ofpossible
preponderance ofhydroxylative pathways
after induction ofhydroxylating enzymes.
Much better is the knowledge about
metabolism of synthetic estrogens and
about drug effects on the latter. Two estro-
genic compounds are currently used for oral
contraception, 17-ot-ethinylestradiol and its
3-methyl ether, mestranol. In humans,
about half of a mestranol dose is trans-
formed into the hormonally active
ethinylestradiol (6). The major pathway of
ethinylestradiol metabolism (2,3) is aro-
matic hydroxylation at C-2 (to a lesser
degree also at C-4), mainly by cytochrome
P450 3A4. In humans, an average of 30%
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of ingested ethinylestradiol is o-hydroxy-
lated (at C-2/C-4; 7). Another pathway is
deethinylation (1,8-10). Deethinylated
metabolites are reported (9) to comprise 15
to 20% ofthe total glucuronide metabolites
ofethinylestradiol in urine. The initial step
ofde-ethinylation probably is oxygenation
ofthe ethinyl triple bond by a microsomal
monooxygenase (10). Other possible path-
ways of metabolism ofethinylestradiol are
hydroxylations at ring B (C-6) or at the 16-
3-position ofring D (2).
Compounds which interact with these
estrogen hydroxylations have a potential
effect on the biological activity ofsynthetic
estrogen.
Induction ofHydroxylatingEnzymes
The "prototype" ofan inducer ofoxida-
tive drug metabolism, phenobarbital, has
been found to decrease the uterotrophic
action of ethinylestradiol, mestranol and
diethylstilbestrol in rats (11). Barbiturates
enhance ring-3-hydroxylation ofethinyles-
tradiol in man (12), but as this metabolic
route is only a minor one, its biological sig-
nificance is limited. However, rat experi-
ments (13) have shown that phenobarbital
also stimulates aromatic hydroxylation of
ethinylestradiol in rats.
Hempel and co-workers (14) have
studied 51 patients receiving oral contra-
ceptives of the combination type and dif-
ferent amounts ofphenobarbital. Thirty
patients showed spottings and/or break-
through bleedings indicating insufficient
effectivity of the estrogenic component of
the contraceptive; one patient became
pregnant.- This, along with the data of the
animal experiments, very much indicates
that increased breakdown ofsteroid contra-
ceptives occurs in man after phenobarbital
administration. This is especially important
in epileptic patients where barbiturates
and/or related compounds are prescribed
for long-term treatment.
Diphenylhydantoin which often is
combined with these drugs in the manage-
ment of epilepsy may also enhance aro-
matic hydroxylation of estrogens in some
strains of rats (15). When studying 25
cases of "pill failure," Hempel et al. (14)
found four patients among those who were
under antiepileptic therapy. Also, Janz and
Schmidt (16) reported that three patients
became pregnant while taking antiepilep-
tics (primidone, phenobarbital, and
diphenylhydantoin) and oral contraceptives
ofthe combination type. A similar case has
been reported by Nenyon (17).
It also has been claimed (14) that
administration ofsome analgesics together
with oral contraceptives should result in
increased rate of breakthrough bleedings;
however, the validity ofthese data not been
confirmed.
By far, the most potent inducer of
estrogen-metabolizing enzymes in man is
the antituberculous drug rifampicin.
Rifampicin is also known to interfere with
the effectiveness of several other drugs
including anticoagulants (18,19), tolbu-
tamids (20-22), cardiac glycosides (23)
and barbiturates (21,22).
Reimers and Jezek (24) reported in
1971 that simultaneous administration of
rifampicin and oral contraceptives resulted
in increased incidence of spotting and
breakthrough bleedings. According to a
study by Nocks-Finck et al. (25), five preg-
nancies occurred in 88 patients treated
with rifampicin and oral contraceptives.
The authors suggested that this effect may
be due to enzyme induction (26).
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Subsequently, several other reports also
showed a diminished antifertility effect of
oral contraceptives, if the patients were
under treatment with rifampicin (27-30).
In 1973, Remmer et al. (31,32)
demonstrated that rifampicin causes induc-
tion of drug metabolism enzymes in the
endoplasmic reticulum of human liver.
Obviously, there are marked species differ-
ences in inductive response to rifampicin.
Administration of the compound to mice
increases hepatic cytochrome P450,
NADPH-cytochrome c reductase and
hydroxylation of drugs (33, 34) while in
rats only NADPH-cytochrome c reductase
increases (35, 36). When patients are
treated with the usual therapeutic dose of
60 mg/day rifampicin for 6 to 10 days,
hepatic microsomal cytochrome P450
increases 2- to 3-fold (31,37). Later, it has
been found that rifampicin especially
induces human liver cytochrome P450 3A4
(3). Liver microsomes from patients
treated with rifampicin also show about a
4-fold increase in their ability to o-hydrox-
ylate estradiol and ethinylestradiol, com-
pared to those from untreated normal
subjects (37). It has already been men-
tioned above that aromatic hydroxylation
is the major pathway in the metabolism of
synthetic estrogens.
Further studies (7) examined the influ-
ence ofrifampicin treatment on the phar-
macokinetics of ethinylestradiol.
Ethinylestradiol, when given to humans,
showed a biphasic plasma t1/2 of7.5 ± 1.7
SD) hr in the second (fi) phase.
Administration of rifampicin (600 mg
daily for 6 days) shifted this half-life to 3.3
± 0.9 hr while the apparent volume ofdis-
tribution was not changed. Moreover, the
rate ofaromatic hydroxylation in man has
been determined using (2,4,6,7- H)
labeled ethinylestradiol. After administra-
tion of this compound, determination of
the tritiated water (H3HO) formed pro-
vides a sensitive tool to follow aromatic
hydroxylation. The initial rate ofoxidation
of (2,4,6,7-3H-)-ethinylestradiol is
increased more than 2-fold by rifampicin
treatment (7). The data which have been
elaborated in man therefore show that
rifampicin induces the estrogen-2-hydroxy-
lase in the endoplasmic reticulum of
human liver, and explain the markedly
reduced effectiveness ofestrogens in con-
traceptives, ifthe patients are treated with
rifampicin.
Endogenous hormones may respond to
enhanced breakdown with an increase of
their secretion rate so that changes due to
enzyme induction become even more com-
plex. This view is confirmed by the obser-
vation ofEdwards et al. (38) that secretion
of cortisol is increased in patients treated
with rifampicin. In guinea pigs (39) and in
man (40) rifampicin also induces 6-n-
hydroxylation ofcortisol. It is also ofinter-
est that rifampicin treatment apparently
increases oxidative metabolism of some
synthetic glucocorticoids, e.g., methylpred-
nisolone (41).
Inhibition of Hydroxylating
Enzymes and Role of Liver
Damage
Experimentally, SKF 525A has a moderate
inhibitory effect on hepatic microsomal
aromatic hydroxylation ofnatural and syn-
thetic estrogens (13). A much stronger
inhibitory effect has been reported to be
due to some compounds ofthe 1,2,2-ben-
zothiaciazole and arylimidazole classes
which were designed as insecticide syner-
gists (42). The most potent inhibitor of
this class, 1-napthyl-4(5)-imidazole, inhib-
ited aromatic hydroxylation ofethinylestra-
diol by a Ki of 3 x 10-6M. Hence, the
estrogen-inactivating system may be sus-
ceptible to inhibition by possible environ-
mental pollutants such as insecticide
synergists.
With regard to endogenous estrogenic
hormones, the effect of liver damage on
estrogen metabolism is ofconsiderable clin-
ical importance (3) as one ofthe symptoms
seen in man suffering from hepatic cirrho-
sis is gynecomastia (43,44). Zumoff et al.
(45) have observed a decrease of2-hydrox-
ylation ofendogenous estrogens in patients
with liver cirrhosis along with an increase
of 16-a-hydroxylation. The same is
observed in rats with thioacetimide-
induced liver fibrosis (46,47). The primary
lesion seems to be destruction of the spe-
cific cytochrome P450 species that cat-
alyzes 2-hydroxylation of estrogens (48).
Experimentally 2-hydroxylation of
ethinylestradiol is also impaired in liver
damage; this effect ofsynthetic sex steroids
on metabolism is only oftheoretical inter-
est and has no clinical implications.
EffectofDrugs onEnterohepatic
Circulation ofEsgens
It has been recognized by Sandberg and
Slaunwhite (49) in 1957 that enterohep-
atic circulation is of quantitative impor-
tance for disposition of estrogens in man.
This contrasts to the patterns ofthe other
"neutral" steroid hormones (50). Changes
in metabolism of natural estrogens after
application of ampicillin have been
explained by interference with the entero-
hepatic circulation of estrogens (51).
Recent animal studies (52) are supportive
ofthis view: the antibiotic neomycin, when
orally applied to rats, markedly inhibits
enterohepatic recirculation of metabolites
of estradiol and mestranol by directly
affecting the gut microflora which is
responsible for deconjugation ofthe biliary
steroid conjugates.
Interference ofantibiotics with entero-
hepatic circulation of synthetic estrogens
can be assumed to be ofclinical importance
since three women became pregnant while
taking oral contraceptives together with
ampicillin (53).
Another drug which may interfere with
enterohepatic circulation of estrogens is
cholestyramine which is prescribed in order
to prevent bile acid conjugates from under-
going enterohepatic circulation. This anion
exchange polystyrene resin also binds other
biliary steroid conjugates. It could be
demonstrated that the plasma half-life of
ethinylestradiol in the ,B phase, which
depends on the rate of metabolism of
ethinylestradiol (7), is shortened by
administration ofcholestyramine.
In a normal subject which was studied,
the t1/2 ,B ofethinylestradiol, normally 8.2
hr, was reduced to 4.8 hr under adminis-
tration of3 x 4 g/day cholestyramine. The
apparent volume of distribution was
unchanged. Along with the present data on
impairment ofenterohepatic circulation by
antibiotics, this effect of cholestyramine
could be interpreted in a way that
cholestyramine increases elimination of
ethinylestradiol by preventing it from
enterohepatic recirculation.
Conclusion
While metabolism and efficacy oforal con-
traceptives are influenced by a series of
other drugs, alteration by contraceptive
compounds of other drugs' metabolism is
questionable (54). This must be viewed
along with the low doses ofestrogens and
gestagens used for oral contraception (55).
Pincus (56), in his classical studies on oral
contraception, has used as the estrogenic
component 150 jig mestranol and a high
gestagen dose. Now, the recommended
daily dose ofestrogen in contraceptive for-
mulations is 50/,ug ethinylestradiol or less
(57-59). Thromboembolic side effects of
oral contraceptives are mainly dependent
on the dose of estrogen prescribed; a low
dose ofestrogen decreases the incidence of
such adverse reactions. However, at a lower
dose range, factors which enhance meta-
bolic elimination and thereby dcecrease the
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hormonal effectiveness become even more
important (60). Such factors include induc-
tion of estrogen metabolizing enzymes,
mainly the estrogen-2-hydroxylase, and
interference ofdrugs with the enterohepatic
circulation ofestrogens. Decreased effective-
ness of the estrogenic component of oral
contraceptives results in spottings, break-
through bleedings and "pill failure."
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